Analysts Issue Forecasts for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Investment analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for shares of Genelux in a research report issued on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of ($0.20) for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.16) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Genelux in a report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $18.25.

Genelux Stock Performance

Shares of NASDAQ:GNLX opened at $3.20 on Thursday. Genelux has a 52-week low of $1.60 and a 52-week high of $6.50. The business’s 50 day simple moving average is $4.03 and its two-hundred day simple moving average is $3.09. The firm has a market cap of $110.52 million, a P/E ratio of -3.37 and a beta of -1.41.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in Genelux by 39.7% during the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after acquiring an additional 89,854 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after purchasing an additional 52,958 shares during the last quarter. LPL Financial LLC lifted its position in shares of Genelux by 72.3% during the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after purchasing an additional 39,516 shares in the last quarter. XTX Topco Ltd purchased a new position in Genelux during the third quarter worth about $59,000. Finally, D.A. Davidson & CO. bought a new stake in Genelux in the 4th quarter worth about $51,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.